A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype
Study Evaluates Efficacy and Safety of Exa-cel for Severe Sickle Cell Disease
Plain English Summary
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype is a Phase 3 clinical trial sponsored by Vertex Pharmaceuticals Incorporated studying Sickle Cell Disease. Tests a single dose of Exa-cel to improve symptoms and reduce complications in severe Sickle Cell Disease. For adults and adolescents with severe SCD and βS/βC genotype. Participation involves a single IV infusion followed by monitoring for 2 years. Alternative treatments include regular RBC transfusions and bone marrow transplants.
Official Summary
The purpose of the study is to evaluate the efficacy and safety of CTX001 (exa-cel) in adolescent and adult participants with severe sickle cell disease (SCD), βS/βC genotype (HbSC).
Who Can Participate
Here is what you need to know about eligibility for this trial. Eligible if you have βS/βC genotype and are considered suitable for stem cell transplant. Not eligible if you have a healthy 10/10 HLA-matched donor or have had a stem cell transplant. Age range: 12-65 years. Good overall health, no other serious diseases. This trial is studying Sickle Cell Disease, so participants generally need a confirmed diagnosis.
What They're Measuring
The primary outcome measures the percentage of participants with increased fetal hemoglobin, which can reduce pain crises and improve overall health. The specific primary outcome measures are: Proportion of Participants with an Average Fetal Hemoglobin (HbF) Greater Than or Equal To (>=) 20 percent (%) on or After 6 Months (From 60 Days after Last Red Blood Cell (RBC) transfusion up to 24 Months after exa-cel infusion). These endpoints are how researchers determine whether the treatment is effective and will form the basis of any future regulatory submissions.
About This Phase
This trial is in Phase 3, the final and most rigorous stage before seeking FDA approval. Phase 3 trials involve 300-3,000+ patients across multiple sites and compare the new treatment directly against the current standard of care. These pivotal trials generate the evidence needed for regulatory review. About 58% of Phase 3 drugs receive FDA approval. Successful Phase 3 results typically lead to a New Drug Application submission.
Why This Trial Matters
This trial aims to fill a gap in treatment options for severe Sickle Cell Disease by evaluating a new therapy. As a Phase 3 trial, positive results could directly lead to FDA approval, making this treatment available to the broader patient population. This research targets Sickle Cell Disease, where improved treatment options are needed.
Investor Insight
Market size is significant, with a large unmet need for effective treatments for Sickle Cell Disease. Phase 3 trials have approximately a 50-60% chance of gaining FDA approval if they reach this stage.
Is This Trial Right for Me?
Ask your doctor about your eligibility and the potential benefits and risks. You will receive a single IV infusion and be monitored for 2 years. The trial is being conducted at multiple sites. Always discuss clinical trial participation with your healthcare provider before making any decisions. This information is for educational purposes only and is not medical advice.
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.
Study Design
- Study Type: INTERVENTIONAL
- Allocation: NA
- Model: SINGLE_GROUP
- Masking: NONE
Interventions
- BIOLOGICAL: Exa-cel — Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
Primary Outcomes
- Proportion of Participants with an Average Fetal Hemoglobin (HbF) Greater Than or Equal To (>=) 20 percent (%) on or After 6 Months (From 60 Days after Last Red Blood Cell (RBC) transfusion up to 24 Months after exa-cel infusion)
Secondary Outcomes
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Signing of Informed Consent up to 24 Months After exa-cel Infusion)
- Proportion of Participants With Neutrophil Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count (ANC) >=500 per Microliter [mcgL] on 3 Different Days) (Within 42 Days After exa-cel Infusion)
- Time to Neutrophil Engraftment (Up to 24 months After exa-cel Infusion)
- Time to Platelet Engraftment (Up to 24 months After exa-cel Infusion)
- Incidence of Transplant-Related Mortality (TRM) (Up to 100 Days After exa-cel Infusion)
Full Eligibility Criteria
Key Inclusion Criteria: * Participants with documented βS/βC (HbSC) genotype * Participants must be eligible for autologous stem cell transplant as per investigator's judgment Key Exclusion Criteria: * A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement * Participants with prior hematopoietic stem cell transplant (HSCT) * Treatment with regular RBC transfusions that, in the opinion of the investigator, cannot be interrupted after engraftment. Other protocol defined Inclusion/Exclusion criteria may apply.
Frequently Asked Questions
What is clinical trial NCT05951205?
NCT05951205 is a Phase 3 INTERVENTIONAL study titled "Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype." It is currently withdrawn and is sponsored by Vertex Pharmaceuticals Incorporated.
What conditions does NCT05951205 study?
This trial investigates treatments for Sickle Cell Disease. The primary condition under study is Sickle Cell Disease.
What treatments are being tested in NCT05951205?
The interventions being studied include: Exa-cel (BIOLOGICAL). Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
What does Phase 3 mean for NCT05951205?
Phase 3 trials are large-scale studies involving 300-3,000+ patients that compare the new treatment against existing standard treatments. Positive Phase 3 results are typically required for FDA approval.
What is the current status of NCT05951205?
This trial is currently "Withdrawn." It started on 2027-07-31. The estimated completion date is 2033-12-31.
Who is sponsoring NCT05951205?
NCT05951205 is sponsored by Vertex Pharmaceuticals Incorporated. The sponsor is responsible for funding, designing, and overseeing the clinical trial.
How is NCT05951205 designed?
This is a interventional study, uses na allocation, follows a single_group design, employs none masking.
What are the primary outcomes being measured in NCT05951205?
The primary outcome measures are: Proportion of Participants with an Average Fetal Hemoglobin (HbF) Greater Than or Equal To (>=) 20 percent (%) on or After 6 Months (From 60 Days after Last Red Blood Cell (RBC) transfusion up to 24 Months after exa-cel infusion). These are the main endpoints researchers use to determine whether the treatment is effective.
Where can I find official information about NCT05951205?
The official record for NCT05951205 is available on ClinicalTrials.gov at https://clinicaltrials.gov/study/NCT05951205. This government database provides the most up-to-date and detailed information about the trial.
What is NCT05951205 testing in simple terms?
Tests a single dose of Exa-cel to improve symptoms and reduce complications in severe Sickle Cell Disease. For adults and adolescents with severe SCD and βS/βC genotype.
Why is this trial significant?
This trial aims to fill a gap in treatment options for severe Sickle Cell Disease by evaluating a new therapy. As a Phase 3 trial, positive results could lead directly to regulatory approval and new treatment options for patients.
What are the potential risks of participating in NCT05951205?
Risks include potential side effects from the infusion and the conditioning treatment with busulfan. Monitor for signs of infection and other adverse events. As with any clinical trial, participants are closely monitored and can withdraw at any time.
Should I consider participating in NCT05951205?
Ask your doctor about your eligibility and the potential benefits and risks. You will receive a single IV infusion and be monitored for 2 years. Always discuss clinical trial participation with your healthcare provider to determine if it is appropriate for your specific situation.
What does NCT05951205 signal from an investment perspective?
Market size is significant, with a large unmet need for effective treatments for Sickle Cell Disease. This is a Phase 3 trial, which is the final pivotal stage before potential regulatory submission.
What happens if the treatment in this trial doesn't work?
Participation involves a single IV infusion followed by monitoring for 2 years. Participants in clinical trials always have the right to withdraw and pursue alternative treatments. The study team will help transition patients to other available options.
Related Conditions
More Sickle Cell Disease Trials
This analysis is AI-generated and does not constitute medical advice. Always consult your healthcare provider before making decisions about clinical trial participation.